FORMELA JEAN FRANCOIS 4

What Happened

• Formela Jean Francois, a director of Korro Bio (KRRO), sold a total of 175,367 shares in open‑market transactions between June 22 and June 24, 2026, generating total proceeds of approximately $2.46 million. Individual blocks included sales at reported weighted-average prices and specific trades ranging from $13.95 to $15.10 per share (see footnotes for ranges and weighted averages).
• These were sales (not purchases or option exercises). Some of the sales were made pursuant to a Rule 10b5‑1 trading plan adopted by Francois on April 8, 2026, which is a pre-arranged plan that can indicate routine disposition rather than opportunistic timing.

Key Details

• Dates and prices: June 22–24, 2026; reported per‑share prices ranged roughly from $13.95 to $15.10. Reported weighted‑average prices and ranges are provided in the filing (see footnotes F4–F6).
• Shares sold and proceeds (by date blocks reported): total 175,367 shares for ~$2,458,583 (examples: 101,579 shares on 6/23 for $1,447,501; 40,679 shares on 6/24 for $593,913).
• Ownership after transaction: Not specified in the data you provided from the filing.
• Notable footnotes: F1 — some sales were made under a 10b5‑1 plan (adopted 4/8/2026). F2/F3 — several blocks were held by Atlas Venture funds (Atlas XI and AVOF II); Francois is a member of the related general partner entities and disclaims Section 16 beneficial ownership of those fund‑held shares except to the extent of any pecuniary interest.
• Filing timeliness: Form 4 was filed on 2026‑06‑24 for transactions through 2026‑06‑24; the filing appears timely based on the reported dates.

Context

• Sales by company directors are common and may be routine (especially when done under a 10b5‑1 plan). This filing documents dispositions only; it does not by itself indicate the director’s view of Korro Bio’s prospects.
• Several transactions were of shares held by venture funds rather than direct personal holdings; the reporting person disclaims full Section 16 beneficial ownership of those fund shares per the footnotes.